The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR
is involved in several cancer developments, including NSCLC. The EGFR pathway …

Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to
treat patients with EGFR T790M-positive non–small cell lung cancer (NSCLC) who have …

Abstract Purpose: About 60% of non–small cell lung cancer (NSCLC) patients develop
resistance to targeted epidermal growth factor receptor (EGFR) inhibitor therapy through the …

Aberrant expression of microRNA-146a (miR-146a) has been reported to be involved in the
development and progression of various types of cancers. However, its role in non-small cell …

A novel series of small-molecule inhibitors has been developed to target the double mutant
form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to …

Abstract The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small
Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced …

Lung cancer is treated with many conventional therapies, such as surgery, radiation, and
chemotherapy. However, these therapies have multiple undesirable side effects. To bypass …

The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR)
mutated or EML4–ALK rearrangement-positive tumors are sensitive to tyrosine kinase …

Highlights•Comprehensive review of EGFRTK inhibitors.•Helps in understanding the
structural and developmental aspects of small molecular EGFR TKIs.•Focuses on mutant …